Silver
| Address | 6F Haesung-2-Bldg, Teheran-Ro 508, Gangnam-gu, 135-725 Seoul | ||
|---|---|---|---|
| Telephone | 010-7100-8124 | Fax | 02-2185-3939 |
| Website | https://www.merckgroup.com/kr-ko | kun-hyo.park@merckgroup.com | |
"Merck Biopharma Korea founded in 1989 is a Korean subsidiary of Merck which is the oldest pharmaceutical/chemical group with 354 years of history in the world. Merck Biopharma Korea is a healthcare division among three business sectors (healthcare, performance materials and life science) that of Merck Korea which claims to stand for ‘Innovative science and technology leader company’ is operating in Korea. Merck Biopharma Korea continues to grow with the vision ‘creating values for patients and HCPs by developing and supplying innovative medicines’. Especially, we are focusing our efforts on the launch of new specialty pipeline products in line with its strategy to achieve Merck’s global healthcare goal of becoming ‘Global Specialty Innovator.’ It provides therapeutic drugs for immune-oncology, oncology, neurology, immunology, infertility and endocrinology etc and introduces innovative products and technologies that lead the market in specialized fields such as multiple sclerosis, growth hormones and infertility."
ERBITUX® is an epidermal growth factor receptor (EGFR) inhibitor indicated for the treatment of metastatic colorectal cancer (mCRC) and head and neck cancer. ERBITUX® is the standard of care recommended by major guidelines such as NCCN and the ESMO. Large-scale clinical studies have shown that ERBITUX® results in a consistent improvement in overall survival (OS) to more than 30 months and is effective in achieving early tumor shrinkage.Notably, ERBITUX® has also demonstrated an 8-month improvement in OS compared with bevacizumab in patients with left-sided colon cancer.
